Evaluation of the effect of vaginal product based on persian medicine in bacterial vaginosis

Comparison of the effect of vaginal Persian Medicine product based on Cymbopogon olivieri with metronidazole in bacterial vaginosis: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211111053036N1

Enrollment

Registered

2022-02-02

Start date

2022-01-21

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bacterial vaginosis. Acute vaginitis

Interventions

Intervention 1: The intervention group is treated with vaginal 500 mg cymbopogon olivierie capsule prepared from the alcoholic extract powder of the plant. Intervention 2: Control group: Control grou

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: All married women aged 18-50 Symptoms of bacterial vaginitis in patients Patient satisfaction

Exclusion criteria

Exclusion criteria: Complicated patients People with immunodeficiency or diabetes Take any type of corticosteroids Taking ocp drugs Pregnancy Patients' unwillingness to continue the study partner

Design outcomes

Primary

Measure	Time frame
Posetive whiff test. Timepoint: Before treatment and 10 days after treatment. Method of measurement: Laboratory kit.	—

Secondary

Measure	Time frame
The smell of vaginal discharge. Timepoint: Before treatment and 10 days after treatment. Method of measurement: observation.;Inflammation of the external vaginal tract and vagina. Timepoint: Before treatment and 10 days after treatment. Method of measurement: Information collection form.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMitra Esmaili

Kerman University of Medical Sciences

m.esmaili@kmu.ac.ir+98 34 3133 6161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026